Latest news with #analyticalinstruments
Yahoo
3 days ago
- Business
- Yahoo
Waters Holds Jefferies Buy Rating Despite Target Cut, with BD Merger Poised to Boost Long-Term Growth
Waters Corporation (NYSE:WAT) is one of the best agriculture technology stocks to buy now. On August 4, 2025, Jefferies analyst Tycho Peterson reiterated a Buy rating on Waters while trimming the price target from $435 to $385. The revision wasn't a knock on the company's strength, it was a tempered recalibration after a 12% post-merger dip. Jefferies called the Q2 earnings a 'solid beat,' with revenue and EPS both exceeding consensus. A portion of the upside was front-loaded due to tariff pressures, but the firm emphasized that Waters is well-positioned to outperform in the back half of the year. Despite trimming the target, Peterson expressed confidence in the trajectory: raised full-year guidance, strong recurring revenue, and a major upcoming merger with Becton Dickinson's diagnostics arm all point to scale, synergies, and a wider moat. Jefferies noted that the BD merger is being underappreciated by the market and should ultimately reinforce Waters' long-term value proposition. Waters Corporation (NYSE:WAT) is a global leader in analytical instruments and software, serving life sciences, food safety, and agriculture, and offering critical tools in everything from pesticide residue analysis to precision crop science. While we acknowledge the potential of WAT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
24-07-2025
- Business
- Yahoo
Agilent Technologies' Q3 2025 Earnings: What to Expect
Santa Clara, California-based Agilent Technologies, Inc. (A) is a global leader in providing application-focused solutions to the life sciences, diagnostics, and applied chemical markets. Valued at a market cap of $33.9 billion, the company designs and manufactures a broad portfolio of analytical instruments, software, consumables, and services. It is scheduled to announce its fiscal Q3 earnings for 2025 after the market closes on Wednesday, Aug. 27. Before this event, analysts project this healthcare company to report a profit of $1.37 per share, up 3.8% from $1.32 per share in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in each of the last four quarters. Its earnings of $1.31 per share in the previous quarter outpaced the consensus estimates by 4%. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the full year, analysts expect A to report EPS of $5.59, up 5.7% from $5.29 per share in fiscal 2024. Furthermore, its EPS is expected to grow 8.8% year-over-year to $6.08 in fiscal 2026. A has fallen 8.6% over the past 52 weeks, underperforming both the S&P 500 Index's ($SPX) 14.5% return and the Health Care Select Sector SPDR Fund's (XLV) 8.3% loss over the same time frame. Agilent Technologies reported impressive Q2 performance on May 28, and its shares surged 2.2% in the following trading session. Due to growth in its life sciences and diagnostics markets revenue and a rise in CrossLab segment's sales, the company's overall revenue improved 6% year-over-year to $1.7 billion, topping consensus estimates by 2.5%. Moreover, its adjusted EPS of $1.31 advanced 7.4% from the prior-year quarter, exceeding Wall Street expectations by 4%. A's effective Ignite Transformation initiative supported its Q2 results. Looking ahead to fiscal 2025, A expects revenue to range between $6.7 and $6.8 billion, and projects adjusted EPS in the range of $5.54 to $5.61. Wall Street analysts are moderately optimistic about A's stock, with an overall "Moderate Buy" rating. Among 16 analysts covering the stock, eight recommend "Strong Buy," and eight advise 'Hold.' The mean price target for A is $138.57, indicating a 16% premium from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
